Advancing Precision Therapies for Kidney Diseases: Chinook's Pipeline and Clinical Progress Overview | Eric Dobmeier, CEO, Chinook Therapeutics Inc. 00:10:00

Share On Facebook Share On Twitter

Chinook Therapeutics, led by Eric Dobmeier, is advancing precision therapies for kidney diseases. Their lead program, Atrocentin, targets IgA nephropathy, while Biom1301 and Check 336 offer promising treatments for various conditions. With a focus on rare chronic kidney diseases, Chinook is pioneering new approaches in nephrology.

Recent Videos